AAV2-neurturin (CERE-120) for Parkinson's disease

Bibliography

• Stacy M. Medical treatment of Parkinson disease. Neurol Clin 2009;3:605-31
   Google Scholar
• Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359(23):2468-76
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6
   PubMed Web of Science ®Google Scholar
• Lin LF, Doherty DH, Lile JD, GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260(5111):1130-2
   PubMed Web of Science ®Google Scholar
• Kirik D, Rosenblad C, Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000;12(11):3871-82
   PubMed Web of Science ®Google Scholar
• Wang L, Muramatsu S, Lu Y, Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 2002;9(6):381-9
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290(5492):767-73
   PubMed Web of Science ®Google Scholar
• Choi-Lundberg DL, Lin Q, Chang YN, Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-41
   PubMed Web of Science ®Google Scholar
• Nutt JG, Burchiel KJ, Comella CL, Randomized, double- blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73
   PubMed Web of Science ®Google Scholar
• Kordower JH, Palfi S, Chen EY, Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46(3):419-24
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK, Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59(3):459-66
   PubMed Web of Science ®Google Scholar
• Bankiewicz KS, Forsayeth J, Eberling JL, Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006;14:564-70
   PubMed Web of Science ®Google Scholar
• Herzog CD, Bishop KM, Brown L, Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically-active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv Transl Res 2011;1(5):361-82
   PubMed Web of Science ®Google Scholar
• Hefti F. 1997;Pharmacology of neurotrophic factors. Annu Rev Pharmacol Toxicol 37:239-67
   PubMed Web of Science ®Google Scholar
• Snider WD, Johnson EM Jr. Neurotrophic molecules. Ann Neurol 1989;489-506
   PubMed Web of Science ®Google Scholar
• Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000;20(12):4686-700
   PubMed Web of Science ®Google Scholar
• Kotzbauer PT, Lampe PA, Heuckeroth RO, Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384:467-70
   PubMed Web of Science ®Google Scholar
• Herzog CD, Dass B, Holden JE, Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22:1124-32
   PubMed Web of Science ®Google Scholar
• Gasmi M, Brandon EP, Herzog CD, AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007;27:67-76
   PubMed Web of Science ®Google Scholar
• Kordower JH, Herzog CD, Dass B, Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60:706-15
   PubMed Web of Science ®Google Scholar
• Gasmi M, Brandon EP, Herzog CD, AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007b;27:67-76
   PubMed Web of Science ®Google Scholar
• Herzog CD, Bishop K, Brown L, Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically-active neurotrophic factor proteins for neurodegenerative diseases. Drug deliv Transl Res 2011;1:361-82
   PubMed Web of Science ®Google Scholar
• Gasmi M, Herzog CD, Brandon EP, Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007;15:62-8
   PubMed Web of Science ®Google Scholar
• Emborg ME, Ma SY, Mufson EJ, Age-related declines in nigral neuronal function correlate with motor impairments in rhe- sus monkeys. J Comp Neurol 1998;401:253-65
   PubMed Web of Science ®Google Scholar
• Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007;25:134-49
   PubMed Web of Science ®Google Scholar
• Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc atl Acad Sci 1982;79:2077-e2081
   PubMed Web of Science ®Google Scholar
• Kaplitt MG, Leone P, Samulski RJ, Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8(2):148-54
   PubMed Web of Science ®Google Scholar
• Weinberg MS, Samulski RJ, McCown TJ. Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Herzog CD, Dass B, Gasmi M, Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol. Ther 2008;16:1737-44
   PubMed Web of Science ®Google Scholar
• Herzog CD, Brown L, Gammon D, Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease. Neurosurgery 2009;64:02-612
   Google Scholar
• Marks WJ Jr, Ostrem JL, Verhagen L, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7(5):400-8
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Bartus RT, Siffert J, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9(12):1164-72
   PubMed Web of Science ®Google Scholar
• Bartus RT, Herzog CD, Chu Y, Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011;26(1):27-36
   PubMed Web of Science ®Google Scholar
• Lewis TB, Standaert DG. Parkinson's disease, primates, and gene therapy: vive la difference? Mov Disord 2011;26(1):2-3
   PubMed Web of Science ®Google Scholar
• Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin). San Diego, CA: ceregene/Press Release, 5/17/12. Avaliable from www.ceregene.com/press_051712.asp [Last accessed 14 July 2012]
   Google Scholar
• Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenera- tive diseases. Prog Neurobiol 1999;57:451-84
   PubMed Web of Science ®Google Scholar
• Braak H, Sandmann-Keil D, Gai W, Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 1999;265:67-9
   PubMed Web of Science ®Google Scholar
• Roy S, Zhang B, Lee VM, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropath 2005;109:5-13
   PubMed Web of Science ®Google Scholar
• Morfini GA, Burns M, Binder LI, Axonal transport defects in neurodegenerative diseases. J Neurosci 2009;29:12776-86
   PubMed Web of Science ®Google Scholar
• Ceregene Advances Phase2b CERE-120 (AAV2-Neurturin) Trial in Parkinson's Disease. San Diego, CA: Ceregene/Press Release, 02/03/11. Avaliable from www.ceregene.com/press_020311.asp [Last accessed 14 July 2012]
   Google Scholar
• Manfredsson FP, Tumber N, Erdos B, Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009;17:980-91
   PubMed Web of Science ®Google Scholar
• Su X, Kells AP, Huang EJ, Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009;20:1627-40
   PubMed Web of Science ®Google Scholar
• Bartus RT, Brown L, Wilson A, Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011;44(1):38-52
   PubMed Web of Science ®Google Scholar
• Benabid AL, Pollak P, Gross C, Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 1994;62(1–4):76-84
   PubMedGoogle Scholar
• Williams A, Gill S, Varma T, PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9(6):581-91
   PubMed Web of Science ®Google Scholar
• Freed CR, Greene PE, Breeze RE, Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344(10):710-19
   PubMed Web of Science ®Google Scholar
• Lindvall O, Rehncrona S, Brundin P, Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989;46(6):615-31
   PubMed Web of Science ®Google Scholar
• Lindvall O, Brundin P, Widner H, Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990;247(4942):574-7
   PubMed Web of Science ®Google Scholar
• Lindvall O, Sawle G, Widner H, Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35(2):172-80
   PubMed Web of Science ®Google Scholar
• Peschanski M, Defer G, N'Guyen JP, Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994;117(Pt 3):487-99
   PubMedGoogle Scholar
• Wenning GK, Odin P, Morrish P, Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997;42(1):95-107
   PubMed Web of Science ®Google Scholar
• Hagell P, Schrag A, Piccini P, Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 1999;122(Pt 6):1121-32
   PubMed Web of Science ®Google Scholar
• Spencer DD, Robbins RJ, Naftolin F, Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992;327(22):1541-8
   PubMed Web of Science ®Google Scholar
• Olanow CW, Goetz CG, Kordower JH, A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54(3):403-14
   PubMed Web of Science ®Google Scholar
• Meyer AK, Maisel M, Hermann A, Restorative approaches in Parkinson's Disease: which cell type wins the race? J Neurol Sci 2010;289(1-2):93-103
   PubMed Web of Science ®Google Scholar
• Arenas E. Towards stem cell replacement therapies for Parkinson's disease. Biochem Biophys Res Commun 2010;396(1):152-6
   PubMed Web of Science ®Google Scholar
• Tsui A, Isacson O. Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol 2011;258(8):1393-405
   PubMed Web of Science ®Google Scholar
• Venkataramana NK, Pal R, Rao SA, Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study. Stem Cells Int 2012;2012:931902
   PubMedGoogle Scholar
• Mesenchymal stem cells transplantation to patients with Parkinson's disease. Avaliable from www.clinicaltrials.gov/ct2/show/NCT01446614?term=stem+cell+parkinson&rank=2 [Last accessed 14 July 2012]
   Google Scholar
• Park S, Kim E, Koh SE, Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior. Brain Res 2012;1466:158-66
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Rezai AR, Leehey MA, 2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10(4):309-19
   PubMed Web of Science ®Google Scholar
• Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee. Fort Lee, NJ:Neurologix/Press Release, 6/8/11. Available from: phx.corporate-ir.net/phoenix.zhtml?c=106413&p=irol-newsArticle&ID=1572034&highlight= [Last accessed 16 July 2012]
   Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355(9):896-908
   PubMed Web of Science ®Google Scholar
• Prosavin improves symptoms of Parkinson's disease. Avaliable from http://www.oxfordbiomedica.co.uk/page.asp?pageid=17 [Last accessed 20 August 2012]
   Google Scholar
• Eberling JL, Jagust WJ, Christine CW, Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008;70(21):1980-3
   PubMed Web of Science ®Google Scholar